Bio-Techne Corp (TECH) financial statements and ratios from SEC XBRL: revenue $1.2B (TTM), net margin 15.0%, revenue growth 1.3% YoY, P/E 89.1. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $1.22B |
| Revenue (TTM) | $1.2B |
| Net Margin | 15.0% |
| Return on Equity | 6.0% |
| Operating Margin (TTM) | 20.7% |
| Current Ratio | 4.55 |
| Net Debt / EBITDA | 0.0 |
| Interest Coverage | 26.2 |
| Revenue Growth (YoY) | 1.3% |
| FCF Growth (YoY) | -6.8% |
| P/E Ratio | 89.1 |
| Price / Book | 5.38 |
| Price / Sales | 9.33 |
| Dividend Yield | 0.4% |
| FCF Yield | 2.3% |
| Altman Z-Score | 15.84 (safe) |
| Piotroski F-Score | 8/9 |
| Piotroski checks passed | 8 of 9 |
| Industry P/E (Pharmaceutical Products) | 16.0 |
| Sector P/E (Healthcare) | 21.5 |
TECH overview · TECH earnings · TECH KPIs · TECH documents · TECH ownership · TECH peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.